(Q38411334)

2 September 2017

1 reference

title

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis (English)

1 reference

2 September 2017

1 reference

Atsushi Ogata

1

1 reference

2 September 2017

Takayoshi Morita

series ordinal

2

1 reference

2 September 2017

Yuji Yoshida

series ordinal

3

1 reference

2 September 2017

Toshio Tanaka

series ordinal

4

1 reference

2 September 2017

1 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

6

1 reference

2 September 2017

3

1 reference

2 September 2017

283-295

1 reference

The pathogenesis of rheumatoid arthritis

2 September 2017

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Long-term consequences of interleukin-6 overexpression in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Pathological role of interleukin-6 in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

The impact of biologic response modifiers on hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Interleukin-6 in pregnancy and gestational disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FTDE.14.118

21 January 2018

Identifiers

DOI

10.4155/TDE.14.118

1 reference

2 September 2017

1 reference